<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30–7:40am</td>
<td>Program Overview and Objectives</td>
<td>Stephen Nimer, MD</td>
<td>Sylvester Cancer Center, University of Miami</td>
</tr>
<tr>
<td>7:40–8:15am</td>
<td>New WHO Classification of MDS</td>
<td>Robert Hasserjian, MD</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>8:15–8:50am</td>
<td>Integrating Molecular Findings into the Diagnosis and Prognosis of MDS</td>
<td>Rafael Bejar, MD, PhD</td>
<td>Moores Cancer Center, University of California, San Diego</td>
</tr>
<tr>
<td>8:50–9:25am</td>
<td>Recent Insights into Therapy-related MDS</td>
<td>Richard Larson, MD</td>
<td>University of Chicago</td>
</tr>
<tr>
<td>9:25–10:00am</td>
<td>Emerging Immune-related Therapies in MDS/AML</td>
<td>Daniel T. Starczynowski, PhD</td>
<td>Cincinnati Children's Hospital Medical Center</td>
</tr>
<tr>
<td>10:00–10:35am</td>
<td>Novel Treatment of Biologic and Molecular Targets for MDS-related Anemias and Higher Risk Disease</td>
<td>Uwe Platzbecker, MD</td>
<td>University Hospital &quot;Carl Gustav Carus&quot;</td>
</tr>
<tr>
<td>10:35–11:00am</td>
<td>Questions/Answers/Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Presentations today

• Epidemiology

• Pathobiology, Diagnosis and Prognosis (Drs. Hasserjian, Bejar & Larson)

• Therapies (Dr. Starczynowski, Dr. Platzbecker)
New WHO Classification of MDS

Robert Hasserjian, MD
Massachusetts General Hospital
Integrating Molecular Findings into the Diagnosis and Prognosis of MDS

Rafael Bejar, MD, PhD
Moores Cancer Center, University of California San Diego
Observational study

2500 adults suspected or newly diagnosed with
- MDS
- MDS/MPN
- ICUS

Creating a national resource containing
- Biospecimens
- Clinical data
- Genetic data

Seeking academic sites; NCTN & NCORP funding and credit provided

The National Myelodysplastic Syndromes Natural History Study

Sponsored by the National Heart, Lung, and Blood Institute in collaboration with the National Cancer Institute

Additional Information Available:
NHLBI Booth (#3215) and
https://thenationalmdsstudy.net

NCT02775383
Recent Insights into Therapy-related MDS
Richard Larson, MD
University of Chicago
Emerging Immune-related Therapies in MDS/AML

Daniel T. Starczynowski, PhD
Cincinnati Children's Hospital Medical Center
Novel Treatment of Biologic and Molecular Targets for MDS-related Anemias and Higher Risk Disease

Uwe Platzbecker, MD
University Hospital "Carl Gustav Carus"
About the MDS Foundation, Inc.

Mission: The MDS Foundation, Inc. (MDSF) is an international organization devoted to the support and education of patients and healthcare providers with innovative research in the fields of MDS and related myeloid neoplasms, in order to accelerate progress leading to the control and cure of these diseases.

Vision: By building an international community of physicians, researchers, and patients, we will make potentially curative therapies available for all patients with MDS.

The Professional Impact of the Foundation:

• Over the last 5 years, the MDSF has awarded nearly $300,000 in research grants
• There are approximately 250 researchers participating in our Centers of Excellence program and International Working Groups
• Our professional reach spans 37 countries on 6 continents
Young Investigator
Grant Announcement

- Any investigator, 40 years or younger, is invited to submit an MDS related proposal.
- The award is $25,000
- Applications are due by February 5, 2017.
Living proof

November 30 (2029)
BP=101/70, HR=70, O2=98, Temp=97.9, 172 lb.,
Glucose=111

November 29 (2028)
BP=103/69, HR=81, O2=98, Temp=98.1, 170 lb.,
Glucose=112

November 28 (2027)
BP=113/74, HR=72, O2=99, Temp=97.8, 170.5 lb.,
Glucose=134

November 27 (2026)
BP=102/83, HR=74, O2=99, Temp=98.1, 171.5 lb.,
Glucose=92

November 26 (2025)
BP=112/77, HR=74, O2=98, Temp=98, 171.5 lb.,
Glucose=121

November 25 (2024)
BP=106/74, HR=79, O2=98, Temp=97.8, 173 lb.,
Glucose=130

November 24 (2023)
BP=111/66, HR=80, O2=98, Temp=97.9, 174.5 lb.,
Glucose=132

November 23 (2022)
BP=112/83, HR=81, O2=98, Temp=98, 175 lb.,
Glucose=134

November 22 (2021)